Department of Surgery, Nantong Tumor Hospital, Tumor Hospital Affiliated to Nantong University, Nantong, China.
Department of Oncology, Affiliated Hospital of Nantong University, Nantong, China.
J Clin Lab Anal. 2022 Oct;36(10):e24673. doi: 10.1002/jcla.24673. Epub 2022 Aug 29.
Hepatocellular carcinoma (HCC) accounts for 85%-90% of primary liver cancer. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by targeting the 3'UTR of mRNA. Abnormal expression and regulation of miRNAs are involved in the occurrence and progression of HCC, and miRNAs can also play a role in the diagnosis and treatment of HCC as oncogenes or tumor suppressors.
In the past decades, a large number of studies have shown that miRNAs play an essential regulatory role in HCC and have potential as biomarkers for HCC. We reviewed the literature to summarize these studies.
By reviewing the literature, we retrospected the roles of miRNAs in the development, diagnosis, treatment, and prognosis of HCC, and put forward prospects for the further research on miRNAs in the precision treatment of HCC.
MicroRNAs are important regulators and biomarkers in the occurrence, progression, outcome, and treatment of HCC, and can provide new targets and strategies for improving the therapeutic effect of HCC.
肝细胞癌（HCC）占原发性肝癌的 85%-90%。微小 RNA（miRNA）是一种通过靶向 mRNA 的 3'UTR 来调节基因表达的小非编码 RNA。miRNA 的异常表达和调控参与了 HCC 的发生和发展，miRNA 也可以作为癌基因或肿瘤抑制基因在 HCC 的诊断和治疗中发挥作用。
在过去的几十年中，大量的研究表明 miRNA 在 HCC 中起着至关重要的调节作用，并且具有作为 HCC 生物标志物的潜力。我们回顾了文献，对这些研究进行了总结。
通过对文献的回顾，我们回顾了 miRNA 在 HCC 的发生、诊断、治疗和预后中的作用，并对 miRNA 在 HCC 精准治疗中的进一步研究提出了展望。
miRNA 是 HCC 发生、进展、结局和治疗的重要调节因子和生物标志物，可为提高 HCC 治疗效果提供新的靶点和策略。
